IL3RA and acute myeloid leukemia: Ehninger et al. have explored CD123 and CD33 expression in a cohort of 319 AML patients and showed that AMLs with adverse cytogenetics express CD123 at levels comparable to those with favorable and intermediate subtypes [60].